Company Overview and News

4
Tata Petrodyne may be sold to Invenire Energy

2018-09-12 livemint
Mumbai: Invenire Energy Pvt. Ltd will likely acquire Tata Petrodyne Ltd (), the upstream oil and gas business of the diversified Tata Group, said three people aware of the matter. Invenire Energy is backed by a consortium of private equity firms for the potential deal, the people who didn’t wish to be named said in an interview. The transaction is expected to close shortly, they said without disclosing the estimated value of the deal.
TATAPOWER CAIRN CWNQY 500470 HINDOILEXP TTST 532792 TATASTEEL TATLY TPCL 500400 500570 TATAMOTORS 500186 TTM

 
Vedanta bags 41 oil blocks in open acreage auction

2018-08-29 freepressjournal.in
New Delhi : Mining mogul Anil Agarwal-led Vedanta has bagged 41 out of 55 oil and gas exploration blocks offered in India’s maiden open acreage auction, upstream regulator DGH said on Tuesday.
HINDOILEXP BPCL 500547 BRQPY 500186

 
Government notifies incentives to oil PSUs in pre-NELP blocks

2018-08-15 moneycontrol
The government has notified a new policy requiring state owned Oil and Natural Gas Corp (ONGC) and Oil India Ltd (OIL) to pay royalty and cess tax only to the extent of their equity holding in certain pre-1999 oil and gas fields.
533106 HINDOILEXP CNE OIL CRNZF 500186 CRNCY

 
Vedanta set to bag 40 oil blocks, ONGC 2, HOEC 1

2018-08-07 livemint
New Delhi: Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India’s maiden open acreage auction, people familiar with the matter said on Tuesday.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY

 
Vedanta set to bag 40 oil blocks, ONGC 2, HOEC 1

2018-08-07 moneycontrol
Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India's maiden open acreage auction, official sources said today. An Empowered Committee of Secretaries (ECS) has cleared award of blocks offered in OALP-1, bidding for which closed on May 2, they said.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY

 
HOEC rises 4% on completion of two well re-entry, side track drilling

2018-07-13 moneycontrol
Shares of Hindustan Oil Exploration Company (HOEC) added 4.7 percent intraday Friday as company completed two well re-entry and side track drilling campaign which commenced in April 2018.
HINDOILEXP 500186

 
JK Cement, Omaxe Auto results on Saturday

2018-05-11 thehindubusinessline
The boards of Alkali Metals, Bajaj Hindusthan, Gallant Ispat, Gallant Metal, Hindustan Oil Exploration, JK Cement, LGB Forge, Omaxe Auto, PTC India Financial, Vinati Organics and Vardhman Textiles will meet on Saturday for Q4/FY18 results for the period ended March 2018. The JK Cement board will also consider issuance of NCDs on private placement. SORIL Holdings and Ventures will consider a preferential issue/price for equity shares to foreign investors.
VTL 533007 533029 HINDOILEXP 500820 LGBFORGE ALKALI 524200 502986 VINATIORGA ASIANPAINT 500186

 
Hindustan Oil Exploration Company (₹129.8): Buy

2018-05-09 premium.thehindubusinessline
The stock of Hindustan Oil Exploration Company has been on a short-term uptrend since taking support at around ₹100 in early March this year.
HINDOILEXP 500186

 
Tata Group’s business restructuring plan hits a ‘hydrocarbon’ hurdle

2018-04-19 livemint
Mumbai: Tata Petrodyne Ltd, which has put up its six oil and gas blocks for sale, is yet to find interest from buyers, two people aware of the matter said.
HINDOILEXP 532792 TATAPOWER TPCL 500400 500186 CAIRN CWNQY

2
Deadline for bidding oil and gas blocks extended to May 2

2018-03-22 thehindubusinessline
The government on Thursday pushed back by a month the last date of bidding for a record number of oil and gas blocks to May 2.
533106 HINDOILEXP 532792 OIL 500186 CAIRN VEDL CWNQY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...